CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to shorten CLL treatment
Disease control Recruiting nowThis phase 2 trial tests two oral drugs, zanubrutinib and sonrotoclax, in 24 people with untreated high-risk CLL/SLL. The goal is to see if a time-limited treatment guided by minimal residual disease (MRD) can achieve deep remission. Participants take the drugs for up to 27 cycle…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill combo aims to keep blood cancer at bay
Disease control Recruiting nowThis phase 2 trial is testing a combination of two oral drugs, DZD8586 and venetoclax, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have not yet been treated. The study will first check safety, then see if the combination can keep the ca…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Tough-to-Treat blood cancers: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called DZD8586 against standard treatments in 250 adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to prior therapy. The main goal is to see if DZD8586 can delay cancer growth longer than the d…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for blood cancer patients: experimental drug DZD8586 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called DZD8586 (Birelentinib) in 155 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or not responded to prior treatment. Participants take one of three daily doses to see if the drug shrinks tumors an…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New trial aims to bring targeted lymphoma drugs to minority patients
Disease control Recruiting nowThis phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for …
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug targets Hard-to-Treat blood cancers in chinese trial
Disease control Recruiting nowThis study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for CLL patients: a drug that may spare the heart
Disease control Recruiting nowThis study tests whether acalabrutinib, a drug similar to ibrutinib, is safer for the heart in people with chronic lymphocytic leukemia (CLL). Many patients on ibrutinib develop heart side effects and have to stop treatment. Researchers will give acalabrutinib to 61 adults with C…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Seema Bhat • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo therapy aims to control blood cancer without a cure
Disease control Recruiting nowThis study tests a new drug combination (ICP-248 plus orelabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combination is safe and tolerable. About 226 adults aged 18 to 80 with measurable disease and a need…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Exercise may strengthen immunity in CLL and NHL patients, study suggests
Knowledge-focused Recruiting nowThis study looks at how short-term and long-term exercise affects the immune system in people with slow-growing blood cancers like chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL). Researchers at Mayo Clinic will have 70 participants undergo a 12-week ex…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Tiny heart monitor tracks dangerous rhythms in cancer patients
Knowledge-focused Recruiting nowThis study is for people starting a type of cancer drug called BTK inhibitors, which can sometimes cause irregular heartbeats. Researchers will implant a small heart monitor under the skin to watch for these heart rhythm problems continuously for up to 5 years. The goal is to lea…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: NA • Sponsor: Northwell Health • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:46 UTC